Amgen Inc. (NASDAQ:AMGN) Shares Sold by Brooklyn Investment Group

Brooklyn Investment Group decreased its position in Amgen Inc. (NASDAQ:AMGN) by 5.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,190 shares of the medical research company’s stock after selling 187 shares during the quarter. Brooklyn Investment Group’s holdings in Amgen were worth $831,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Sax Wealth Advisors LLC acquired a new stake in shares of Amgen during the fourth quarter worth approximately $252,000. Somerset Trust Co grew its position in shares of Amgen by 3.3% during the fourth quarter. Somerset Trust Co now owns 19,183 shares of the medical research company’s stock worth $5,000,000 after buying an additional 621 shares in the last quarter. Merit Financial Group LLC grew its position in shares of Amgen by 31.3% during the fourth quarter. Merit Financial Group LLC now owns 18,643 shares of the medical research company’s stock worth $4,859,000 after buying an additional 4,447 shares in the last quarter. Butensky & Cohen Financial Security Inc. grew its position in shares of Amgen by 2.0% during the fourth quarter. Butensky & Cohen Financial Security Inc. now owns 16,248 shares of the medical research company’s stock worth $4,235,000 after buying an additional 312 shares in the last quarter. Finally, Boston Common Asset Management LLC grew its position in shares of Amgen by 3,060.3% during the fourth quarter. Boston Common Asset Management LLC now owns 21,711 shares of the medical research company’s stock worth $5,659,000 after buying an additional 21,024 shares in the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Price Performance

Shares of Amgen stock opened at $272.11 on Friday. Amgen Inc. has a 52 week low of $253.30 and a 52 week high of $346.85. The company has a current ratio of 1.32, a quick ratio of 0.96 and a debt-to-equity ratio of 7.55. The company’s 50-day moving average price is $275.01 and its two-hundred day moving average price is $307.49. The stock has a market cap of $146.27 billion, a PE ratio of 34.84, a price-to-earnings-growth ratio of 2.68 and a beta of 0.56.

Amgen (NASDAQ:AMGN) last announced its earnings results on Wednesday, October 30th. The medical research company reported $5.58 EPS for the quarter, beating the consensus estimate of $5.11 by $0.47. The business had revenue of $8.50 billion during the quarter, compared to the consensus estimate of $8.50 billion. Amgen had a return on equity of 168.35% and a net margin of 13.00%. Amgen’s revenue was up 23.2% compared to the same quarter last year. During the same period in the prior year, the business posted $4.96 earnings per share. As a group, sell-side analysts anticipate that Amgen Inc. will post 19.57 EPS for the current fiscal year.

Amgen Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, February 14th will be paid a $2.38 dividend. This is an increase from Amgen’s previous quarterly dividend of $2.25. This represents a $9.52 annualized dividend and a yield of 3.50%. The ex-dividend date of this dividend is Friday, February 14th. Amgen’s dividend payout ratio is currently 115.24%.

Analysts Set New Price Targets

A number of research firms have recently weighed in on AMGN. Royal Bank of Canada decreased their price target on shares of Amgen from $360.00 to $330.00 and set an “outperform” rating for the company in a research report on Wednesday, November 27th. Sanford C. Bernstein began coverage on Amgen in a research note on Thursday, October 17th. They set an “outperform” rating and a $380.00 price objective on the stock. Citigroup reduced their price objective on Amgen from $335.00 to $310.00 in a research note on Wednesday, November 27th. Cantor Fitzgerald restated an “overweight” rating and set a $405.00 price objective on shares of Amgen in a research note on Tuesday, October 22nd. Finally, TD Cowen raised their price objective on Amgen from $381.00 to $383.00 and gave the stock a “buy” rating in a research note on Monday, October 21st. Two analysts have rated the stock with a sell rating, twelve have assigned a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $314.91.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.